Abstract
To elucidate the role of trypsin inhibitor, inhibitory activity of these drugs in vitro, stability in serum and effect on exocrine pancreatic secretion were studied using clinically applicable trypsin inhibitors-Trasylol, ρ-ethoxycarbonyl-phenyl-guanidinocaproate phosphate (Synthetic I) and 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (Synthetic II).
The change in inhibitory activity together with the electrolytes and enzymes in human and canine pancreatic juice was also measured after the administration of these inhibitors.
The pattern of dose related curve in inhibitory activity of these trypsin inhibitors in vitro was similar to each, revealing that the dosis of 95% inhibition of standard trypsin solution (0.1mg of Sigma trypsin) was 500KIU in Trasylol, 2mg in Synthetic I and 4mg in Synthetic II.
In serum, Trasylol was stable but the inhibitory activity of the synthetic inhibitors was gradually decreased, showing 60% decrease in Synthetic I and 30% decrease in Synthetic II after 120min.
By the intravenous administration of these exogenous trypsin inhibitors, inhibitory activity in serum and pancreatic juice was not influenced. The ratio of secreted trypsin inhibitor to trypsin in pancreatic juice was the approximately same in every experiment, indicating significant correlation in some of them. Therefore, it was suggested that the exogenous trypsin inhibitors in the dosis of this study were neither secreted into human or canine pancreatic juice nor enhanced the secretion of the endogenous trypsin inhibitor into pancreatic juice.
The volume, electrolytes and enzymes of pancreatic juice were also unchanged, and each enzyme was secreted in parallel fashion before and after the administration of trypsin inhibitors.
Then, it was concluded that trypsin inhibitors in the dosis of this study did not play any secretagogous or secretoinhibitory role.
